文献速递腹部技术与安全US

对比增强超声LI-RADS 2017版评估:在乙型肝炎病毒感染患者2020个肝结节中的应用

Evaluation of Contrast-enhanced US LI-RADS version 2017: Application on 2020 Liver Nodules in Patients with Hepatitis B Infection.
PubMed 文献 · Radiology · 2019-11-26

该回顾性研究纳入2004年1月至2016年12月评估的1826例HBV感染患者的2020个肝结节,按CE US LI-RADS 2017版分类,以组织学或复合影像及临床随访为标准。LR-5对HCC的PPV为98%;将具有动脉期高增强、早期廓清且5分钟内无穿凿样表现的LR-M结节重新分类为LR-5后,LR-M特异度和PPV分别从88%和36%升至96%和58%,LR-5特异度和PPV仍保持94%和98%。

要点

  • CE US LI-RADS 2017版LR-5对HCC的阳性预测值为98%(95%CI:98%,99%)。
  • LR-M中具有动脉期高增强、早期廓清且5分钟内无穿凿样表现者,93%为HCC。
  • 将上述LR-M结节重新分类为LR-5后,LR-M特异度和PPV分别升至96%和58%。

核心结论

  • CE US LI-RADS 2017版LR-5能有效预测肝细胞癌的存在。
  • 在HBV感染患者中,将具有动脉期高增强、早期廓清且无穿凿样表现的LR-M结节重新分类为LR-5,可能进一步提高诊断性能。

研究设计与样本

  • 回顾性研究,纳入1826例HBV感染患者的2020个肝结节,中位年龄54岁±12(标准差),男性1642例,评估时间为2004年1月至2016年12月。
  • 采用对比增强超声LI-RADS 2017版将结节分类为LR-1至LR-5及LR-M,并对LR-M subgroup重新分类为LR-5进行补充分析。
  • 参考标准为组织学评估或复合影像及临床随访结果。

关键影像表现/征象

  • 1159个LR-5病灶中,1141个为肝细胞癌,3个为肝内胆管癌,6个为其他恶性肿瘤,6个为不典型增生,3个为良性病变。
  • LR-M结节中,153个表现为动脉期高增强、早期廓清且5分钟内无穿凿样表现,其中142个(93%;95%CI:89%,97%)为HCC。

诊断标准与关键数值

  • LR-5对HCC的PPV为98%(95%CI:98%,99%)。
  • LR-M作为非HCC恶性肿瘤预测指标的特异度和PPV分别为88%(95%CI:87%,89%)和36%(95%CI:31%,41%)。
  • 将具有动脉期高增强、早期廓清且5分钟内无穿凿样表现的LR-M结节重新分类为LR-5后,LR-M特异度和PPV分别升至96%(95%CI:95%,97%)和58%(95%CI:51%,65%)(P < .001)。
  • 重新分类后,LR-5特异度和PPV仍保持较高,分别为94%(95%CI:92%,96%)和98%(95%CI:97%,99%)。

临床应用与阅片要点

  • CE US LI-RADS 2017版LR-5类别对HCC具有高度阳性预测价值。
  • 在HBV感染患者中,对具有动脉期高增强、早期廓清且5分钟内无穿凿样表现的LR-M结节,可考虑重新分类为LR-5以改善诊断性能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Use of contrast material-enhanced (CE) US Liver Imaging Reporting and Data System (LI-RADS) version 2017 has not been validated in large populations where hepatitis B virus (HBV) is endemic. Purpose To evaluate the diagnostic performance of CE US LI-RADS version 2017 in a population with a high prevalence of HBV infection. Materials and Methods In this retrospective study, liver nodules in patients with HBV who were evaluated from January 2004 to December 2016 were categorized as CE US LR-1 to LR-5 through LR-M. A subgroup of LR-M nodules was reclassified as LR-5, and additional analysis was performed. The reference standard consisted of histologic evaluation or composite imaging and clinical follow-up findings. Diagnostic performance was assessed with sensitivity, specificity, positive predictive value (PPV), and negative predictive value. Results A total of 2020 nodules in 1826 patients (median age, 54 years ± 12 [standard deviation]; 1642 men) were included. Of the 1159 LR-5 lesions, 1141 were hepatocellular carcinoma (HCC); three, intrahepatic cholangiocarcinomas; six, other malignancies; six, atypical hyperplasia; and three, benign lesions. The PPV of LR-5 for HCC was 98% (95% confidence interval [CI]: 98%, 99%). In LR-M nodules, 153 showed arterial phase hyperenhancement, early washout, and absence of punched-out appearance within 5 minutes, and 142 of 153 (93%; 95% CI: 89%, 97%) were HCC. If these nodules were reclassified as LR-5, LR-M specificity and PPV as a predictor of non-HCC malignancy increased from 88% (95% CI: 87%, 89%) and 36% (95% CI: 31%, 41%) to 96% (95% CI: 95%, 97%) and 58% (95% CI: 51%, 65%), respectively (P < .001). Despite reclassification, LR-5 specificity and PPV remained high (94% [95% CI: 92%, 96%] and 98% [95% CI: 97%, 99%], respectively). Conclusion The contrast-enhanced US Liver Imaging Reporting and Data System version 2017 category LR-5 is effectively predictive of the presence of hepatocellular carcinoma. In patients with hepatitis B virus infection, performance may be further improved by reclassification of category LR-M nodules with arterial phase hyperenhancement, early washout, and no punched-out appearance to LR-5. Published under a CC BY 4.0 license. Online supplemental material is available for this article. See also the editorial by Sidhu in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Zheng W, Li Q, Zou XB, et al. Evaluation of Contrast-enhanced US LI-RADS version 2017: Application on 2020 Liver Nodules in Patients with Hepatitis B Infection. Radiology. 2019. PMID: 31769742. doi:10.1148/radiol.2019190878

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。